Every year more than 400.000 people die from malaria. Over 80% of the cases and over 90% of the deaths occur in sub-Saharan Africa. Every 2 minutes a child dies from the disease. As the causative parasite continues to escape from human immune responses, the development of new effective malaria therapies remain a strong medical need.
DMG Deutsche Malaria is currently developing a non-artemisinin combination drug to treat uncomplicated falciparum malaria (clinical study phase I/IIa successfully finished) and a triple drug combination against severe malaria (clinical trials will commence soon).